Lexicon Pharmaceuticals (LXRX) Return on Sales (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, up 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (up 5.0% YoY), and the FY2025 annual result was 0.01%, up 5.0% from the prior year.
• Return on Sales improved to 0.0% in Q1 2026 per LXRX's latest filing, from 0.03% in the prior quarter.
• Over five years, Return on Sales peaked at 19.39% in Q2 2022 and troughed at 3.3% in Q3 2023.
• A 5-year average of 1.32% and a median of 0.03% in 2025 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales surged 2017 bps in 2022, then slumped 2085 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 3.65% in 2022, then tumbled by 117 bps to 0.61% in 2023, then surged by 98 bps to 0.01% in 2024, then sank by 118 bps to 0.03% in 2025, then surged by 98 bps to 0.0% in 2026.
• Business Quant data shows LXRX's Return on Sales at 0.0% in Q1 2026, 0.03% in Q4 2025, and 0.01% in Q3 2025.